Pyxis Oncology is a clinical stage oncology company focused on developing antibody drug conjugates for solid tumors. The company’s lead candidate micvotabart pelidotin also known as MICVO targets the splice variant of fibronectin known as EDB+FN within the tumor extracellular matrix. By binding to this non cellular component MICVO releases a cytotoxic payload that kills cancer cells directly induces a bystander effect and stimulates immunogenic cell death. The company is advancing MICVO in recurrent metastatic head and neck squamous cell carcinoma both as monotherapy and in combination with pembrolizumab. In addition to its lead program Pyxis Oncology maintains a pipeline of earlier stage assets that leverage its proprietary conjugation and antibody discovery platforms. The company’s research also explores the potential of MICVO in other solid tumor types such as breast, lung, and ovarian cancers where EDB+FN is over expressed.

Pyxis Oncology generates revenue primarily through collaboration and licensing agreements. The company has a clinical trial collaboration and supply agreement with Merck to evaluate MICVO in combination with pembrolizumab which may trigger milestone payments upon achievement of predefined development goals. It also holds exclusive licenses from Pfizer for the FACT conjugation platform and from Biosion for the APXiMAB antibody discovery platform as well as a license from the University of Chicago for certain immunotherapy targets. Under these agreements Pyxis Oncology is entitled to receive upfront fees milestone payments and royalties on net sales of any resulting products. Additionally the company has monetized non core assets such as selling its interest in the Simcere Royalty Agreement for an upfront amount. In December 2025 the company entered into an amendment to the Simcere Royalty Agreement whereby it relinquished future royalties in exchange for an upfront payment of $11 million.

Pyxis Oncology occupies a distinct position within the oncology biotechnology landscape as a developer of antibody drug conjugates that target the tumor stroma rather than cancer cell surfaces. This approach differentiates it from conventional ADCs that bind to surface antigens and places it alongside other stromal targeting initiatives while also competing with established ADC makers such as Seagen, Pfizer, and Daiichi Sankyo. In the head and neck space the company faces competition from immunotherapy and bispecific antibody developers including Merck, Genmab, Bicara, and Johnson & Johnson. Pyxis Oncology’s competitive advantages stem from its focus on EDB+FN a protein that is minimally expressed in normal tissues but over expressed in many solid tumors which may reduce off target effects. The company also benefits from its proprietary platforms: the Flexible Antibody Conjugation Technology enables site specific drug attachment with a consistent drug to antibody ratio and the APXiMAB platform supports the discovery of antibodies against difficult targets. Together these factors aim to improve the therapeutic index of its candidates compared with traditional approaches. The addressable market for recurrent metastatic head and neck squamous cell carcinoma is estimated to exceed 30,000 new cases annually in the United States alone representing a significant unmet need for effective therapies.

Pyxis Oncology’s current customers are its collaboration and licensing partners which include Merck, Pfizer, Biosion, and the University of Chicago. These partners provide funding through upfront payments, milestone achievements, and royalty streams while also contributing technical expertise and clinical trial materials. In the future the company intends to serve patients diagnosed with recurrent metastatic head and neck squamous cell carcinoma as well as hospitals, oncology clinics, and healthcare providers that will administer its therapies upon regulatory approval. Additionally payers such as insurance companies and government health programs will become customers once the product is reimbursed. Beyond MICVO the company’s pipeline includes earlier stage programs such as PD 1 inhibitors and CD40 agonists that are currently deprioritized to concentrate resources on its lead candidate.